Abstracts tagged "rheumatoid arthritis"

Abstract Number: 2165 • 2014 ACR/ARHP Annual Meeting
Myeloid-Derived Suppressor Cells in Rheumatoid Arthritis: Friend or Foe?
Fanlei Hu¹, Chunqing Guo², Xiang-Yang Wang² and Zhanguo Li¹, ¹Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ²Department of Human and Molecular Genetics, Virginia Commonwealth University School of Medicine, Richmond, VA
Background/Purpose Although myeloid-derived suppressor cells (MDSCs) have been linked to T-cell tolerance, their role in rheumatoid arthritis (RA) remains exclusive. Here, we investigated the potential…
Abstract Number: 519 • 2014 ACR/ARHP Annual Meeting
Patterns of Tocilizumab Use and Safety in Patients with Rheumatoid Arthritis: Interim Results from a Multinational Observational Study
Boulos Haraoui¹, Gustavo Casado², Elke Theander³, Laszlo Czirják⁴, Andrew Taylor⁵, Peter Button⁶, Lykke Hinsch Gylvin⁷ and Roberto Caporali⁸, ¹Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, ²Hospital Militar Central, Buenos Aires, Argentina, ³Skane University Hospital Malmö, Lund University, Malmö, Sweden, ⁴University of Pécs, Pécs, Hungary, ⁵Royal Perth Hospital, Perth, Australia, ⁶Roche Products Pty Limited, Dee Why, Australia, ⁷F. Hoffmann-La Roche, Basel, Switzerland, ⁸Rheumatology, Division of Rheumatology, University of Pavia, IRCCS Policlinico San Matteo, Pavia, Italy
Background/Purpose: Tocilizumab (TCZ) is indicated for the treatment of patients with RA who have had inadequate responses to DMARDs either as monotherapy (Mono) or in…
Abstract Number: 135 • 2014 ACR/ARHP Annual Meeting
Comparison of the Ultrasonography Images and Synovial Pathology of the Joints in Patients with Rheumatoid Arthritis Treated with Biological Agents
Asami Abe¹, Hajime Ishikawa¹ and Akira Murasawa², ¹Rheumatology, Niigata Rheumatic Center, Shibata, Japan, ²Niigata Rheumatic Center, Shibata, Japan
Background/Purpose: An early diagnosis and tight disease control have increased in importance in the era of biological therapy for rheumatoid arthritis (RA). Ultrasonography (US) of…
Abstract Number: 2879 • 2014 ACR/ARHP Annual Meeting
Epigallocatechin-3-Gallate (EGCG) Suppresses IL-1β-Induced IL-6 and IL-8 Synthesis By Selectively Inhibiting TAK1 Activation in Human Rheumatoid Arthritis Synovial Fibroblasts
Anil Singh¹, Sharayah Riegsecker², Sadiq Umar¹ and Salahuddin Ahmed¹, ¹Department of Pharmaceutical Sciences, Washington State University, Spokane, WA, ²Department of Pharmacology, University of Toledo, Toledo, OH
Background/Purpose: In rheumatoid arthritis (RA), the role of interleukin-1β (IL-1β) signaling proteins (IRAK-1/TAK-1/TRAF-6) proximal to IL-1 receptor in mediating proinflammatory response is not completely understood.…
Abstract Number: 1972 • 2014 ACR/ARHP Annual Meeting
Analysis of Anakinra in Primary Human Cell Systems Reveals an in Vitro Signature for Skin-Related Side Effects
Ellen L. Berg, Alison O'Mahony and Mark A Polokoff, BioSeek, South San Francisco, CA
Background/Purpose The therapeutic options for treatment of rheumatic diseases have grown and now include a variety of inflammatory pathway inhibitors, with diverse mechanisms, but having…
Abstract Number: 517 • 2014 ACR/ARHP Annual Meeting
Real-World Use of Tocilizumab in Rheumatoid Arthritis Patients in Canada: Interim Results
Boulos Haraoui¹, Shahin Jamal², Vandana Ahluwalia³, Tarang Manchanda⁴ and Majed Khraishi⁵, ¹Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, ²Department of Rheumatology, University of British Columbia, Vancouver, BC, Canada, ³William Osler Health Center, Brampton, ON, Canada, ⁴Hoffmann-La Roche Canada, Mississauga, ON, Canada, ⁵Nexus Clinical Research, St John's, NF, Canada
Background/Purpose Tocilizumab (TCZ) has been approved for the treatment of adults with rheumatoid arthritis (RA) either as monotherapy or as combination with disease-modifying antirheumatic drugs…
Abstract Number: 123 • 2014 ACR/ARHP Annual Meeting
Combination with Joint Power Doppler Signals with Anti-Citrullinated Peptide Antibody Predicts Joint Destruction in Rheumatoid Arthritis
Yohei Kirino¹, Maasa Hama¹, Kaoru Minegishi-Takase¹, Yosuke Kunishita¹, Daiga Kishimoto¹, Ryusuke Yoshimi¹, Yukiko Asami¹, Atsushi Ihata², Shigeru Ohno³, Atsuhisa Ueda¹, Mitsuhiro Takeno⁴ and Ishigatsubo Yoshiaki¹, ¹Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Department of Rheumatology, Yokohama Minami Kyosai Hospital, Yokohama, Japan, ³Center for Rheumatic Diseases, Yokohama City University Medical Center, Yokohama, Japan, ⁴Clinical Laboratory Department, Yokohama City University Hospital, Yokohama, Japan
Background/Purpose , Categorizing RA patients who require intensive treatments is highly warranted to optimize the therapy and to avoid overtreatments. We here evaluated the use…
Abstract Number: 2817 • 2014 ACR/ARHP Annual Meeting
Histone Deacetylase One Contributes to the Auto-Aggressive Phenotype of Rheumatoid Arthritis
Sarah Hawtree¹, Munitta Muthana¹, J. Mark Wilkinson², Anthony G. Wilson¹ and Mohammed Akil³, ¹Infection and Immunity, University of Sheffield, Sheffield, United Kingdom, ²Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, United Kingdom, ³Rheumatology Department, Sheffield South Yorkshire, United Kingdom
Background/Purpose Rheumatoid arthritis (RA) is a chronic, autoimmune, inflammatory disease that affects synovial joints. A key characteristic of RA is hyperplasia of fibroblast-like synoviocytes (FLS)…
Abstract Number: 1845 • 2014 ACR/ARHP Annual Meeting
Tocilizumab Combination Therapy or Monotherapy or Methotrexate Monotherapy in Methotrexate-Naive Patients with Early Rheumatoid Arthritis: 2-Year Clinical and Radiographic Results from a Randomized, Placebo-Controlled Trial
Gerd Burmester¹, William Rigby², Ronald F. van Vollenhoven³, Jonathan Kay⁴, Andrea Rubbert-Roth⁵, Ricardo Blanco⁶, Ariella Kelman⁷, Sophie Dimonaco⁸ and Nina Mitchell⁸, ¹Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany, ²Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Karolinska Institute, Stockholm, Sweden, ⁴UMass Memorial Medical Center, Worcester, MA, ⁵University of Cologne, Cologne, Germany, ⁶Hospital Marques de Valdecilla, Santander, Spain, ⁷Genentech, South San Francisco, CA, ⁸Roche Products Ltd., Welwyn Garden City, United Kingdom
Background/Purpose: Treatment with tocilizumab (TCZ) in combination with MTX or as monotherapy (Mono) in MTX-naive patients (pts) with early RA resulted in improved signs and…
Abstract Number: 508 • 2014 ACR/ARHP Annual Meeting
Relationship Between NK Cell Count and Important Safety Events in Rheumatoid Arthritis Patients Treated with Tofacitinib
R. van Vollenhoven¹, Y. Tanaka², R. Riese³, M. Lamba³, T. Kawabata³, T. Hirose⁴, S. Toyoizumi⁴, A. Hazra³ and S. Krishnaswami³, ¹The Karolinska Institute, Stockholm, Sweden, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Pfizer Inc, Groton, CT, ⁴Pfizer Inc, Tokyo, Japan
Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Cytokines (e.g. interleukin [IL]-2, -4, -7, -15, -21) involved…
Abstract Number: 2785 • 2014 ACR/ARHP Annual Meeting
Joint Specific Positional Differences in Coding and Noncoding Transcriptome of Synovial Fibroblasts As a Determinant of the Susceptibility of Synovial Joints to Rheumatoid Arthritis
Caroline Ospelt¹, Maria Armaka², Giancarlo Russo³, Anna Bratus³, Michelle Trenkmann⁴, Emmanuel Karouzakis¹, Christoph Kolling⁵, Renate E. Gay⁴, George Kollias⁶, Steffen Gay¹ and Mojca Frank Bertoncelj¹, ¹Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Institute of Immunology,, Biomedical Sciences Research Center 'Alexander Fleming', Vari, Greece, ³Functional Genomics Center Zurich, ETH Zurich and University of Zurich, Zurich, Switzerland, ⁴Center of Experimental Rheumatology, Zurich University Hospital, Zurich, Switzerland, ⁵Schulthess Clinic, Zurich, Switzerland, ⁶Institute of Immunology, Biomedical Sciences Research Center 'Alexander Fleming', Vari, Greece
Background/Purpose The molecular mechanisms underlying the topographic differences in the susceptibility of synovial joints to develop rheumatoid arthritis (RA) are unknown. Positional embryonic expression of…
Abstract Number: 1512 • 2014 ACR/ARHP Annual Meeting
Therapeutic Efficacy of a Novel Oral Small Molecule Macrophage Migration Inhibitory Factor [MIF] Inhibitor: A Promising Safe & Efficacious Treatment for Rheumatoid Arthritis
Anderson Gaweco^1,2, Samantha Palmer², Rambon Shamilov², Caroline Stremnitzer², Michael Fisher², Gregg Crichlow², William Windsor², Ellen M. Ginzler³ and Jefferson Tilley², ¹SUNY-Downstate Medical Center, Brooklyn, NY, ²Innovimmune Biotherapeutics, Brooklyn, NY, ³Rheumatology, SUNY-Downstate Medical Center, Brooklyn, NY
Background/Purpose: Macrophage migration inhibitory factor [MIF] is a cytokine secreted by activated T cells and macrophages that plays an important role in RA and autoimmune…
Abstract Number: 511 • 2014 ACR/ARHP Annual Meeting
First and Second Line Continuation Rates of Non Anti-TNF-α Biological DMARD for the Treatment of Rheumatoid Arthritis
Tristan Pascart¹, Rene-Marc Flipo², Xavier Deprez³ and Eric Houvenagel⁴, ¹Rheumatology, Saint-Philibert Hospital, Lille, France, ²Rheumatology, University Hospital Lille, Lille, France, ³Rhumatologie, Ch De Valenciennes, Valenciennes, France, ⁴Rheumatology, Saint-Philibert Hospital, LOMME, France
Background/Purpose The 2013 update of the EULAR recommendations for the management of RA with synthetic and biological DMARDs set non-anti-TNF- α as first-line biological treatments.…
Abstract Number: 2329 • 2013 ACR/ARHP Annual Meeting
Improvements In Physical Function Correlate With Improvements In Health Related Quality Of Life: Reported Outcomes In Rheumatoid Arthritis Patients Treated With Tofacitinib: Results From 3 Randomized Phase 3 Trials
V. Strand¹, R. E. Alten², C. I. Nduaka³, R. Riese³, D. Gruben³, S. H. Zwillich³, J. Andrews³ and G. Wallenstein³, ¹Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, ²Department of Internal Medicine II, Schlosspark-Klinik, University Medicine, Berlin, Germany, ³Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). RA affects all domains of health-related quality of…
Abstract Number: 1429 • 2013 ACR/ARHP Annual Meeting
Adiponectin Levels Are Increased After Tocilizumab Therapy Among Adults With Rheumatoid Arthritis: Results From The Measure Study
Hoda Mirjafari¹, Micki Klearman², Jianmei Wang³, Naveed Sattar⁴ and Jon T. Giles⁵, ¹Arthritis Research UK Epidemiology Unit, Institute of Inflammation and Repair, Manchester Academic Health Science Centre; The University of Manchester; and Roche;, Manchester, United Kingdom, ²Roche, South San Francisco, CA, ³Roche Products Ltd., Welwyn Garden City, United Kingdom, ⁴University of Glasgow, Glasgow, United Kingdom, ⁵Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY
Background/Purpose: Cardiovascular disease (CVD) is the leading cause of death in patients (pts) with rheumatoid arthritis (RA). Adiponectin has been shown to have anti-inflammatory and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].